Results from previously published BCMA CAR T trials showed that around 33%–88% of RRMM patients had objective anti‐myeloma responses12, 15, 32, 33, 34 and a median PFS of approximately 7–15 months12, 15, 33, 34 after treatment with anti‐BCMA CAR T cells. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.